Primary care trust reverses decision not to fund trastuzumabBMJ 2005; 331 doi: http://dx.doi.org/10.1136/bmj.331.7526.1162 (Published 17 November 2005) Cite this as: BMJ 2005;331:1162
- Susan Mayor
An NHS primary care trust in England last week reversed its decision not to pay for treating a woman with early breast cancer with trastuzumab (Herceptin). It said that after further consideration and intervention by the secretary of state for health it had decided to fund the anticancer drug because of her “exceptional circumstances.”
North Stoke Primary Care Trust in Staffordshire initially rejected an appeal by 41 year old Elaine Barber to be prescribed trastuzumab, even though her specialist had recommended treatment with the drug. The trust said its decision was based on the fact that its safety and cost effectiveness was currently unconfirmed. It had said, “At this stage the evidence of this [trastuzumab] as a cost effective use of the finite health resources available for North Stoke patients is not confirmed. It would therefore be premature to agree to introduce …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial